Skip to content

AnaptysBio, Inc. ANAB Debt-to-assets

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Pfizer logo
PfizerPFE
0.3×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Biogen logo
BiogenBIIB
0.2×0.0×

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Calculated from AnaptysBio, Inc.’s reported figures.

Based on the most recent quarter.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s debt-to-assets?
AnaptysBio, Inc. (ANAB) reported debt-to-assets of 0× in Q1 2026.
How has AnaptysBio, Inc.'s debt-to-assets changed year-over-year?
AnaptysBio, Inc.'s debt-to-assets decreased by 100.0% year-over-year, from 0× to 0×.
What is the long-term trend for AnaptysBio, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), AnaptysBio, Inc.'s debt-to-assets has grown at a -100.0% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.